The Motley Fool··Jonathan PoncianoBiotech Darling $PRAX Soars 685% as $80.5M Investment Bets on Dual FDA Filings
$PRAX surges 685% annually, securing $80.5M from Driehaus Capital. Two FDA applications pending for neurological therapies with potential $20B+ revenue.
TSMPRAXGHbiotechinstitutional investment